Posted by Michael Wonder on 02 Dec 2024
Gilead’s Trodelvy awaits re-deliberation for reimbursement in Korea following patient petitions, price cut proposal
25 November 2024 - The triple negative breast cancer treatment Trodelvy (sacituzumab govitecan), which drew 100,000 petitions from patients, will undergo re-deliberation by HIRA’s Pharmaceutical Reimbursement Review Committee (PREC).
After persuading its headquarters, Gilead Sciences Korea recently submitted an additional financial sharing plan for Trodelvy to PREC.
